Why this study matters
Joubert syndrome (JBTS) is a rare genetic condition in which changes in genes needed for healthy cilia—tiny structures that help cells sense and respond to their environment—disrupt development and organ function. Variants in CEP290 are a leading genetic cause of JBTS, particularly in people with combined brain, retinal, and kidney involvement. This can include the neurological features of Joubert syndrome alongside retinal disease, such as Leber congenital amaurosis, and kidney disease, including nephronophthisis.
A 2026 study in Human Molecular Genetics examines a recurrent CEP290 variant, c.6271-8T>G, and explores a potential way to address its effects using antisense oligonucleotides (ASOs). The work is important because it moves beyond identifying a disease-causing variant: it tests a precision treatment strategy in cells from an affected child.
Understanding the CEP290 splice variant
Genes contain sections that are used to make protein, called exons, separated by intervening regions called introns. Before a protein is produced, cells must accurately remove introns and join exons together through a process called splicing. A variant near a splice site can interfere with this process, causing the cell to assemble the genetic message incorrectly.
The child studied had Joubert syndrome and two different CEP290 variants, one inherited on each copy of the gene. The researchers focused on the c.6271-8T>G variant, located in intron 46 near exon 46. Using RNA testing in patient-derived fibroblasts—connective-tissue cells grown from the patient—they showed that this variant caused an extra seven DNA-letter segment from the intron to be included in the RNA message.
Although seven letters may sound small, this insertion shifts the way the genetic message is read. The result is a frameshift followed by an early stop signal, predicted to produce a severely shortened CEP290 protein: p.(Asn2091Leufs*12). This provided direct functional evidence that c.6271-8T>G is a pathogenic splice-site variant.
Effects seen in patient cells
CEP290 is important at the ciliary transition zone, a region that helps regulate what enters and exits the cilium. When CEP290 function is disrupted, cilia can become structurally and functionally abnormal.
In the patient’s fibroblasts, the investigators observed fewer cells with primary cilia than in comparison cells. The cilia that were present were often elongated and tortuous, meaning they appeared unusually long and twisted. These cellular findings support the idea that the splice variant impairs CEP290 function in a way that affects ciliary health.
The study also reviewed Brazilian cohorts in which c.6271-8T>G had been found either in two copies or alongside another pathogenic CEP290 variant. The reported clinical features associated with this allele included Leber congenital amaurosis, nephronophthisis, and Joubert syndrome. Together, these observations reinforce that the same CEP290 allele can be associated with a spectrum of cilia-related disease manifestations.
Using exon skipping to bypass the error
The most forward-looking part of the study tested an ASO-based approach. ASOs are short, synthetic pieces of nucleic acid designed to bind a specific RNA sequence. In this case, the goal was not to correct the DNA variant itself. Instead, the ASO was designed to encourage the cell to skip exon 46 when making CEP290 RNA.
This strategy is especially notable because exon 46 is 87 base pairs long. Since 87 is divisible by three, skipping the exon is not predicted to disrupt the protein’s reading frame. The researchers further noted that exon 46 skipping was not predicted to disrupt CEP290 protein structure. In principle, this could allow cells to make a slightly shorter, but potentially functional, CEP290 protein while avoiding the harmful splicing error caused by the variant.
In patient fibroblasts, ASO-mediated skipping of exon 46 improved key laboratory measures. It rescued the abnormal ciliary features and restored CEP290 protein expression at the ciliary transition zone. These results show that the approach could overcome the consequences of the c.6271-8T>G allele in the tested cells.
What this could mean for treatment development
This work represents a targeted therapeutic concept for people whose CEP290 variants lie within exon 46 or interfere with its normal splicing. Rather than developing a separate ASO for every individual variant, an exon-skipping strategy may potentially address multiple disease-causing changes affecting the same exon.
The findings are preclinical: they were obtained in patient-derived fibroblasts, not yet in clinical studies. Still, they establish several essential foundations for future development—confirmation of the molecular defect, evidence of ciliary dysfunction, and a measurable improvement after targeted ASO treatment.
Looking ahead
For families affected by CEP290-related Joubert syndrome, this study illustrates the value of detailed genetic and RNA-based testing. Identifying the exact variant and understanding how it changes RNA splicing can reveal whether a person may fit a future mutation-targeted strategy.
The broader research landscape is increasingly focused on matching treatments to the biology of specific inherited retinal disease and ciliopathy variants. Further studies will need to examine ASO delivery, durability, safety, and effects in disease-relevant tissues. Yet this research provides a compelling example of how understanding one recurrent CEP290 splice variant can point toward a rational, personalized path for therapy development.

